What happened
Investors in Novavax (NASDAQ: NVAX) haven’t had much to celebrate recently, but the stock is rocketing higher on Tuesday. As of 11:30 a.m. ET, Novavax shares were up more than 17%, despite the overall stock market being flat.
So what
In a nutshell, Novavax announced that its updated COVID-19 vaccine candidate showed that it was effective against newer variants of the virus, including those that are dominant in the U.S. and are responsible for a recent rise in COVID-19 infections and hospitalizations.
The tests were performed on small animals and primates. Novavax said its updated shot produced neutralizing antibody responses to the fast-spreading Eris variant, as well as others that are in wide circulation in the U.S.
Now what
Novavax said that it is in the process of submitting applications for its updated vaccine globally, and this recent news is clearly a step in the right direction.
However, it’s important to mention that the company continues to struggle to keep up with its larger competitors like Moderna. And remember that a few months ago, Novavax actually expressed concerns about its ability to survive beyond its current fiscal year, and shares are still about 97% below their pandemic-era highs.
It’s fair to say that if the updated vaccine sells well, Novavax could end up generating the near-term cash flow it needs to survive and focus on bringing other products to market.
10 stocks we like better than Novavax
When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now… and Novavax wasn’t one of them! That’s right — they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of August 21, 2023
Matthew Frankel, CFP® has no position in any of the stocks mentioned. The Motley Fool recommends Moderna. The Motley Fool has a disclosure policy.
